Where are you most likely to survive cancer in Europe?
Cancer survival estimates in Europe highlight notable geographical and economic disparities. Euronews Health explores ...
Business Insider1d
Coherus Biosciences to present final Phase 2 casdozokitug combination data
According to the NCI Surveillance, Epidemiology and End Results Program, there will be an estimated 41,630 new cases and 29,840 deaths from liver and intrahepatic bile duct cancer in the US in 2024.4 ...
The American Journal of Managed Care5d
Treatment Combinations Based in Immune Checkpoint Inhibitors Provide Survival Benefits in CRC
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
Non-tumor cells in pancreatic cancer may reduce the effectiveness of the body's natural immune response
The relationship the immune system and stromal cells in pancreatic cancer can have a significant impact on patients' survival ...
Business Wire9d
Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver
About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...
Medical Xpress11d
Researchers link foodborne toxin to colorectal cancer metastasis
Colorectal cancer is the second-leading cause of cancer death in the United States, but when it's caught early, before it has ...
Knowridge14d
Study discovers a root cause of liver cancer
Liver cancer is one of the deadliest cancers worldwide, often developing silently in an organ crucial for metabolism, energy ...
BioSpace14d
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
According to the American Cancer Society, liver cancer accounts for more than 700,000 deaths globally each year. HCC is commonly aggressive with poor survival rates. As new drugs that effectively and ...
Nasdaq15d
Can-Fite announces 8 year survival for patient in Phase 2 Liver Cancer study
Can-Fite BioPharma (CANF) announced that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase II Liver Cancer Study has an overall survival time of 8 ...